Nabla Bio

Last updated April 6, 2026 at 10:42 AM UTC

Nabla Bio is a Cambridge, MA–based biotech company building a platform for generative drug design that pairs de novo design with patient-relevant laboratory testing. By owning the data, AI, and integrated dry/wet-lab systems as one engine, Nabla aims to design medicines with the properties patients need—binding, developability, cellular function, and in-vivo performance—while enabling partnerships with leading pharmaceutical companies to accelerate drug discovery and bring therapies to patients.